FDA Approves Lilly’s New Rapid-Acting Insulin, Lyumjev

On June 15, the FDA approved Eli Lilly and Company’s (LLE) new drug, Lyumjev. It is a new rapid-acting form of insulin designed to speed the absorption of insulin into the blood stream and resduce A1C levels. Lyumjev is a novel formulation of insulin lispro that controls high blood sugar after meals in adults with type 1 and type 2 diabetes.


Rocket Tickers detected the news event and sent an alert at 10:21 pm. The last trade was at 6:37 pm for $141.50. Eli Lilly’s stock price spiked higher at the market open on June 16 and continued to rise throughout the day. The stock closed at $163.71 for an event-day gain of 15.7%.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!